IN2014MN00380A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN00380A IN2014MN00380A IN380MUN2014A IN2014MN00380A IN 2014MN00380 A IN2014MN00380 A IN 2014MN00380A IN 380MUN2014 A IN380MUN2014 A IN 380MUN2014A IN 2014MN00380 A IN2014MN00380 A IN 2014MN00380A
- Authority
- IN
- India
- Prior art keywords
- comparising
- nanoparticles
- producing
- composition
- active compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006903527A AU2006903527A0 (en) | 2006-06-30 | Methods For The Preparation Of Pharmaceutically Active Compounds in Nanoparticulate Form | |
US91595507P | 2007-05-04 | 2007-05-04 | |
PCT/AU2007/000910 WO2008000042A1 (en) | 2006-06-30 | 2007-06-29 | Methods for the preparation of biologically active compounds in nanoparticulate form |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN00380A true IN2014MN00380A (de) | 2015-06-19 |
Family
ID=38845051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN380MUN2014 IN2014MN00380A (de) | 2006-06-30 | 2007-06-29 |
Country Status (9)
Country | Link |
---|---|
US (4) | US20150164802A1 (de) |
EP (1) | EP2054042B8 (de) |
JP (4) | JP5508003B2 (de) |
AU (1) | AU2007264418B2 (de) |
CA (2) | CA2960377A1 (de) |
DK (1) | DK2054042T3 (de) |
IL (2) | IL195945A (de) |
IN (1) | IN2014MN00380A (de) |
WO (1) | WO2008000042A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014MN00380A (de) | 2006-06-30 | 2015-06-19 | Iceutica Pty Ltd | |
AP3775A (en) * | 2009-04-24 | 2016-08-31 | Iceutica Pty Ltd | Method for the production of commercial nanoparticle and microparticle powders |
SG175308A1 (en) * | 2009-04-24 | 2011-11-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
AU2014202776B2 (en) * | 2009-04-24 | 2016-02-25 | Iceutica Pty Ltd | A Novel Formulation of Indomethacin |
KR101824831B1 (ko) * | 2009-04-24 | 2018-02-02 | 아이슈티카 피티와이 리미티드 | 신규 멜록시캄 제제 |
MX351930B (es) * | 2009-04-24 | 2017-11-03 | Iceutica Pty Ltd | Una formulacion novedosa de indometacina. |
SG10201401705VA (en) * | 2009-04-24 | 2014-08-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
MY168079A (en) * | 2009-04-24 | 2018-10-11 | Iceutica Pty Ltd | A novel formulation of diclofenac |
AU2010239159C1 (en) * | 2009-04-24 | 2014-10-16 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
AU2014208310C1 (en) * | 2009-04-24 | 2020-01-23 | Iceutica Pty Ltd | A Novel Formulation of Diclofenac |
AU2016200397B2 (en) * | 2009-04-24 | 2017-08-17 | Iceutica Pty Ltd | A Novel Formulation of Indomethacin |
KR20160135370A (ko) * | 2009-04-24 | 2016-11-25 | 아이슈티카 피티와이 리미티드 | 신규의 나프록센 제제 |
PH12015501811A1 (en) * | 2009-04-24 | 2019-03-25 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
AU2014201967B2 (en) * | 2009-04-24 | 2015-09-17 | Iceutica Pty Ltd | A Novel Formulation of Naproxen |
JP6116243B2 (ja) * | 2009-04-24 | 2017-04-19 | イシューティカ ピーティーワイ リミテッド | メタキサロンの新規製剤 |
WO2010146407A1 (en) * | 2009-06-19 | 2010-12-23 | Nanoform Hungary Ltd. | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
US9937128B2 (en) | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
CN102770125B (zh) * | 2009-12-22 | 2015-02-11 | 利奥制药有限公司 | 钙泊三醇一水化合物纳米晶体 |
WO2012027366A2 (en) | 2010-08-23 | 2012-03-01 | President And Fellows Of Harvard College | Acoustic waves in microfluidics |
US20120141589A1 (en) * | 2010-08-23 | 2012-06-07 | Basf Se | Particles for drug delivery and other applications |
WO2012085927A2 (en) * | 2010-12-02 | 2012-06-28 | Mylan Laboratories, Limited | Tadalafil compositions |
WO2012107541A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
EP2672959A1 (de) | 2011-02-10 | 2013-12-18 | Synthon BV | Granulierte zusammensetzung mit tadalafil und einem sprengmittel |
CN105121559A (zh) | 2013-02-08 | 2015-12-02 | 巴斯夫欧洲公司 | 通过反应喷雾干燥的无机/有机复合材料的制备 |
US9138381B2 (en) | 2013-02-08 | 2015-09-22 | Basf Se | Production of inorganic-organic composite materials by reactive spray-drying |
US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
HU231309B1 (hu) * | 2014-02-25 | 2022-11-28 | Darholding Kft. | Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra |
KR101742152B1 (ko) * | 2014-02-27 | 2017-06-01 | 바로돈에스에프주식회사 | 비특이성 면역증강제 조성물 및 그 제조방법, 그리고 그 용도 |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
US10258987B2 (en) | 2014-06-26 | 2019-04-16 | President And Fellows Of Harvard College | Fluid infection using acoustic waves |
EP3341116B1 (de) | 2015-08-27 | 2022-03-16 | President and Fellows of Harvard College | Sortiermethode unter verwendung von akustischen wellen |
CA3042888A1 (en) * | 2016-11-30 | 2018-06-07 | Druggability Technologies Ip Holdco Limited | Pharmaceutical formulation containing tadalafil |
US11701658B2 (en) | 2019-08-09 | 2023-07-18 | President And Fellows Of Harvard College | Systems and methods for microfluidic particle selection, encapsulation, and injection using surface acoustic waves |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
DE3312671A1 (de) | 1983-04-08 | 1984-10-11 | Heinz Finzer KG, 7880 Bad Säckingen | Stanz- und biegewerkzeug-aggregat |
GB8328929D0 (en) | 1983-10-29 | 1983-11-30 | Sterwin Ag | Steroid compounds |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
IL112746A (en) | 1994-03-02 | 1999-12-31 | Lilly Co Eli | Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride |
US5500331A (en) | 1994-05-25 | 1996-03-19 | Eastman Kodak Company | Comminution with small particle milling media |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5478705A (en) | 1994-05-25 | 1995-12-26 | Eastman Kodak Company | Milling a compound useful in imaging elements using polymeric milling media |
US5631369A (en) | 1994-08-31 | 1997-05-20 | Eli Lilly And Company | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
CA2231050A1 (en) * | 1995-09-07 | 1997-03-13 | Biovail International Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
US6713494B1 (en) | 1996-08-28 | 2004-03-30 | Eli Lilly And Company | Amorphous benzothiophenes, methods of preparation and methods of use |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
JPH10167968A (ja) * | 1996-10-09 | 1998-06-23 | Takeda Chem Ind Ltd | マイクロパーティクルの製造法 |
AU4571097A (en) | 1996-10-09 | 1998-05-05 | Takeda Chemical Industries Ltd. | A method for producing a microparticle |
ZA987800B (en) | 1997-08-27 | 1999-06-09 | Hexal Ag | Pharmaceutical composition of meloxicam |
PL343491A1 (en) | 1998-04-18 | 2001-08-27 | Glaxo Group Ltd | Pharmaceutical aerosol formulation |
AUPP355798A0 (en) * | 1998-05-15 | 1998-06-11 | University Of Western Australia, The | Process for the production of ultrafine powders |
US6165506A (en) | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
JP2000095674A (ja) | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | 口腔内崩壊時間短縮化錠剤の製造方法及び装置 |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
EP2266542A3 (de) * | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
DE19932157A1 (de) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
CA2420597C (en) * | 2000-08-31 | 2011-05-17 | Rtp Pharma Inc. | Milled particles |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
EP1341521B1 (de) * | 2000-11-20 | 2009-01-07 | Elan Pharma International Limited | Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren |
EP2283818B1 (de) | 2000-11-30 | 2017-08-02 | Vectura Limited | Herstellungsverfahren für Partikel zur Verwendung in einer Arrzneizusammensetzung |
FI20010115A0 (fi) | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
AU2002334939A1 (en) | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
JP2005526020A (ja) | 2002-02-01 | 2005-09-02 | ファイザー・プロダクツ・インク | アジスロマイシンの乾式造粒配合物 |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
ITMI20021074A1 (it) | 2002-05-20 | 2003-11-20 | Actimex S R L | Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione |
US20070059356A1 (en) | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP4123834B2 (ja) | 2002-06-10 | 2008-07-23 | 株式会社ダイフク | 移載設備 |
GB0219516D0 (en) | 2002-08-21 | 2002-10-02 | Phoqus Ltd | Fast dissolving and taste masked oral dosage form comprising sildenafil |
JP2004099442A (ja) * | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
US7964734B2 (en) | 2002-09-30 | 2011-06-21 | A/S Gea Farmaceutisk Fabrik | Raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
AU2003297151A1 (en) | 2002-12-17 | 2004-07-22 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
EP1651189B1 (de) | 2003-08-08 | 2008-12-03 | Elan Pharma International Limited | Neue metaxalon-zusammensetzungen |
US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
KR20060104989A (ko) | 2003-10-01 | 2006-10-09 | 데비오 레쉑쉐 빠르마슈띠끄 에스.아 | 미립자 제조 장치 및 방법 |
WO2006009419A1 (es) | 2004-07-19 | 2006-01-26 | Luis Cordova Boone | Neumáticos con doble banda de rodamiento |
KR20060024927A (ko) | 2004-09-15 | 2006-03-20 | 씨제이 주식회사 | 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법 |
WO2006041843A2 (en) | 2004-10-04 | 2006-04-20 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical dosage form comprising meloxicam |
WO2007001451A2 (en) | 2004-11-09 | 2007-01-04 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
EP1830824B1 (de) | 2004-12-31 | 2016-01-13 | Iceutica Pty Ltd. | Nanoteilchen-zusammensetzung und verfahren zu ihrer synthese |
CA2631492A1 (en) | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for oral administration |
EP1973527B1 (de) | 2005-12-15 | 2009-10-07 | Acusphere, Inc. | Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur parenteralen verabreichung |
WO2007070851A2 (en) * | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
US8420122B2 (en) | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
IN2014MN00380A (de) | 2006-06-30 | 2015-06-19 | Iceutica Pty Ltd | |
TWI645862B (zh) | 2006-06-30 | 2019-01-01 | 艾修提卡股份有限公司 | 包含奈米微粒形式生物活性化合物之劑型形式 |
AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
AR067997A1 (es) | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
US8568696B2 (en) | 2008-08-06 | 2013-10-29 | Indiana Nanotech Llc | Grinding method for the manipulation or preservation of calcium phosphate hybrid properties |
JP2010167968A (ja) | 2009-01-23 | 2010-08-05 | Mitsubishi Fuso Truck & Bus Corp | 床構造 |
MX351930B (es) | 2009-04-24 | 2017-11-03 | Iceutica Pty Ltd | Una formulacion novedosa de indometacina. |
SG10201401705VA (en) | 2009-04-24 | 2014-08-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
MY168079A (en) | 2009-04-24 | 2018-10-11 | Iceutica Pty Ltd | A novel formulation of diclofenac |
SG175308A1 (en) | 2009-04-24 | 2011-11-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
KR101824831B1 (ko) | 2009-04-24 | 2018-02-02 | 아이슈티카 피티와이 리미티드 | 신규 멜록시캄 제제 |
JP6116243B2 (ja) | 2009-04-24 | 2017-04-19 | イシューティカ ピーティーワイ リミテッド | メタキサロンの新規製剤 |
AU2010239159C1 (en) | 2009-04-24 | 2014-10-16 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
KR20160135370A (ko) | 2009-04-24 | 2016-11-25 | 아이슈티카 피티와이 리미티드 | 신규의 나프록센 제제 |
AP3775A (en) | 2009-04-24 | 2016-08-31 | Iceutica Pty Ltd | Method for the production of commercial nanoparticle and microparticle powders |
-
2007
- 2007-06-29 IN IN380MUN2014 patent/IN2014MN00380A/en unknown
- 2007-06-29 CA CA2960377A patent/CA2960377A1/en active Pending
- 2007-06-29 DK DK07719147.6T patent/DK2054042T3/da active
- 2007-06-29 AU AU2007264418A patent/AU2007264418B2/en active Active
- 2007-06-29 CA CA2653384A patent/CA2653384C/en active Active
- 2007-06-29 EP EP07719147.6A patent/EP2054042B8/de active Active
- 2007-06-29 WO PCT/AU2007/000910 patent/WO2008000042A1/en active Application Filing
- 2007-06-29 JP JP2009516825A patent/JP5508003B2/ja active Active
-
2008
- 2008-12-15 IL IL195945A patent/IL195945A/en active IP Right Grant
-
2013
- 2013-10-18 JP JP2013217782A patent/JP2014058524A/ja active Pending
-
2014
- 2014-08-18 US US14/461,594 patent/US20150164802A1/en not_active Abandoned
-
2015
- 2015-11-06 JP JP2015218166A patent/JP2016026220A/ja active Pending
-
2016
- 2016-01-10 IL IL243534A patent/IL243534B/en active IP Right Grant
-
2017
- 2017-10-31 JP JP2017210163A patent/JP6651489B2/ja active Active
-
2018
- 2018-06-22 US US16/016,443 patent/US11103456B2/en active Active
-
2021
- 2021-08-30 US US17/461,713 patent/US20220054418A1/en not_active Abandoned
-
2023
- 2023-12-28 US US18/399,546 patent/US20240122855A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20150164802A1 (en) | 2015-06-18 |
EP2054042B8 (de) | 2020-06-10 |
AU2007264418A1 (en) | 2008-01-03 |
US20180369145A1 (en) | 2018-12-27 |
CA2653384C (en) | 2017-03-14 |
US11103456B2 (en) | 2021-08-31 |
JP6651489B2 (ja) | 2020-02-19 |
US20220054418A1 (en) | 2022-02-24 |
IL195945A (en) | 2016-02-29 |
IL195945A0 (en) | 2009-09-01 |
CA2960377A1 (en) | 2008-01-03 |
JP2016026220A (ja) | 2016-02-12 |
JP5508003B2 (ja) | 2014-05-28 |
EP2054042A1 (de) | 2009-05-06 |
JP2014058524A (ja) | 2014-04-03 |
AU2007264418B2 (en) | 2012-05-03 |
US20240122855A1 (en) | 2024-04-18 |
EP2054042B1 (de) | 2020-04-29 |
IL243534B (en) | 2021-03-25 |
EP2054042A4 (de) | 2012-08-15 |
DK2054042T3 (da) | 2020-08-03 |
IL243534A0 (en) | 2016-02-29 |
WO2008000042A1 (en) | 2008-01-03 |
CA2653384A1 (en) | 2008-01-03 |
JP2018058846A (ja) | 2018-04-12 |
JP2009541362A (ja) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN00380A (de) | ||
SG148142A1 (en) | Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof | |
AP2914A (en) | Method for producing 4-oxoquinoline compound | |
IL195341A0 (en) | Methods and materials for making simvastatin and related compounds | |
WO2008051465A3 (en) | Process for making crystalline anhydrous docetaxel | |
NZ593874A (en) | Nalmefene hydrochloride dihydrate | |
EP2130909A4 (de) | Verfahren zur zahnherstellung und damit hergestellter zahn | |
TR201910311T4 (tr) | L-metiyonin öncüsü üreten mikroorganizma ve mikroorganizma kullanarak L-metiyonin öncüsü üretme yöntemi. | |
EP2060349A4 (de) | Verfahren zur herstellung eines durchgangslochs | |
SG143149A1 (en) | Phosphite composition and method for producing the same | |
EP2103603A4 (de) | Verfahren zur herstellung einer pyrrolidinverbindung | |
IL192788A0 (en) | Method for producing steroid compound | |
EP2018394A4 (de) | Herstellung von biowasserstoff durch einen künstlichen enzymweg | |
IL193137A0 (en) | Method of characterizing a biologically active compound | |
EP2061778A4 (de) | Verfahren zur herstellung einer cyclischen ungesättigten verbindung | |
SG146569A1 (en) | Process for producing methionine | |
IL192702A0 (en) | Process for producing 5-alkoxy-4-hydroxymethylpyrazole compound | |
TW200740772A (en) | Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine | |
EP2039698A4 (de) | Phosphormolybdänverbindung und verfahren zu deren herstellung | |
MX2007002924A (es) | Procedimiento de fabricacion de compuestos imidazolicos, sus sales y sus pseudopolimorfos. | |
SG136920A1 (en) | Process for producing methionine | |
SG136932A1 (en) | Method for producing a layer structure | |
EP2050735A4 (de) | Verfahren zur herstellung einer optisch aktiven 3-amino-nitrogenierte verbindung | |
SG143133A1 (en) | Continuous processes for the production of ethoxylates | |
EP2103594A4 (de) | Verfahren zur herstellung einer stickstoffhaltigen verbindung |